Bullish Case: Strong developments in IGMS's clinical pipeline could lead to a substantial price increase, with high implied volatility indicating robust market interest. If breakthroughs occur, the stock may surpass $10, driven by positive sentiment and news.

Bearish Case: The continued trend of mean reversion suggests low price stability, with significant insider selling and declining volumes contributing to uncertainty. A lackluster performance could push IGMS below $5 if market conditions worsen or sentiment remains negative.

Potential Outcomes:

• Breakthrough results driving price above $10: 25%
• Continued mediocre performance around $7: 50%
• Significant declines due to market volatility: 25%

Trading Oracle: Adopt a bearish stance with a sell-to-open strategy on IGMS 12/20/2024 7.50 P, aiming for high IV. Combine with a buy-to-open 5.00 P to kickstart hedging. This setup anticipates the likelihood of downward movement while controlling risk in a volatile environment.

December 18, 2024